FOXO4-DRI

FOXO4-DRI (Forkhead box O4-D-Retro-Inverso) is a synthetic, cell-permeable peptide designed to act as a senolytic agent. It is used in research to selectively induce apoptosis (programmed cell death) in senescent “zombie” cells. The process by interrupting the interaction between the FOXO4 protein and the p53 tumor suppressor.

FDA-Approved Uses

General aging/longevity — restored fitness, fur density, renal function in aged mice (2017 Cell paper)
Kidney disease / CKD — improved kidney tubular cell markers, urea/creatinine metrics
Osteoarthritis — removed senescent chondrocytes from human cell cultures
COPD (chronic obstructive pulmonary disease)
Testosterone decline in aging (Leydig cell senescence improved testosterone in aged mice)
Chemotherapy-induced senescence clearance

Order Now

Trade Names in USA and Manufacturers

Original discovery: Baar et al. (2017) — lead investigators at Erasmus University Medical Center and Princess Maxima Center, Rotterdam, Netherlands
Commercial developer: Cleara Biotech (Rotterdam, Netherlands)
Cleara Biotech is currently pursuing clinical development for kidney disease, COPD, and osteoarthritis
A 2025 Nature Communications study provided detailed structural insights into the FOXO4-p53 interaction mechanism, reinforcing the scientific foundation

Dosage

FOXO4-DRI is used senolyticaly — meaning in SHORT INTERMITTENT CYCLES (clearing senescent cells), NOT continuously.

Animal study reference doses (NOT for human translation):

Mouse studies (Baar et al., 2017):
5 mg/kg intraperitoneal (IP) injection, 3 times per week
Duration: Varied by study protocol

Translation challenge:

Standard allometric scaling would suggest a far lower human-equivalent dose than 5 mg/kg in mice’
Community protocols using 2–5 mg/kg in humans are early adopter choices, NOT FDA-guided conversions
No human pharmacokinetic data exists to guide dosing

Community/grey-market research protocols (reported, NOT endorsed):

Dose: 1–5 mg SC per injection
[Some protocols report 10–25 mg SC for larger body weights]
Frequency: 2–3x per week
Senolytic cycle: 3 consecutive days, then 4–6 week break
[Mirrors the intermittent dosing used with small-molecule senolytics like D+Q (dasatinib + quercetin)]

⚠️ CRITICAL: NEVER combine multiple senolytics simultaneously (FOXO4-DRI + dasatinib + quercetin, etc.)
Allow minimum 4–6 weeks between senolytic courses
Monitor bloodwork (CBC, CMP, inflammatory markers) between courses

Reconstitution:
Lyophilized powder; reconstitute with Bacteriostatic Water or sterile saline
Store at -20°C lyophilized
Use reconstituted solution promptly — D-retro-inverso peptides have excellent stability but sterility is paramount
Purity ≥98% is essential for research use — lower purity DRI peptides may contain toxic synthesis byproducts

Pricing

Research chemical vendors (unregulated):
5 mg vial: ~50–50–100
10 mg vial: ~80–80–150
Monthly cost: Variable — FOXO4-DRI is NOT used daily
A senolytic cycle (e.g., 3 days × 1 mg = 3 mg) may cost ~30–30–60 per cycle
Annual cost (4–6 cycles): ~120–120–360/year for the peptide alone

Note: FOXO4-DRI is relatively expensive per mg compared to simpler peptides due to:
– Highly specialized D-retro-inverso synthesis requirement
– Strict purity standards (≥98% required)
– Limited commercial production scale
– Higher demand from longevity community driving premium pricing

Tips

FOXO4-DRI is the most experimental compound in this document series. There are ZERO completed human clinical trials. All claims are based on mouse studies. The gap between a mouse study and proven human therapy is real — even promising mouse results frequently fail to translate to humans.
Cleara Biotech (Netherlands) is the legitimate commercial developer pursuing clinical trials. Monitor their IND filing and Phase 1 trial initiation announcements — this will be the first opportunity for supervised human data.
The D-retro-inverso (DRI) design is critical: it is what makes FOXO4-DRI stable in vivo and resistant to protease degradation. ONLY purchase from vendors providing HPLC purity ≥98% with CoA confirming D-amino acid content.
The comparator small-molecule senolytic combination D+Q (dasatinib + quercetin) has MORE human clinical trial data than FOXO4-DRI, including actual human Phase 1/2 trials showing reduced senescent cell markers. For patients wanting senolytic therapy with human evidence, D+Q is currently better-validated than FOXO4-DRI.
FOXO4-DRI’s theoretical advantage over D+Q is SELECTIVITY. It targets one specific protein-protein interaction (FOXO4-p53) rather than multiple pathways. But selectivity in mice does not guarantee selectivity in humans.
p53 is the most important tumor suppressor in the human genome. Reactivating p53 in cancer cells could theoretically have anti-tumor effects or in some contexts could have unexpected consequences. Anyone with active malignancy should not use FOXO4-DRI without oncologist consultation.

Side Effects

From the landmark 2017 Cell paper (Baar et al.) and subsequent animal studies:

In aged mice (2017 Cell study):
– No significant toxicity to healthy cells or tissues observed
– Blood panels remained normal after treatment
– No weight loss (typical of toxic compounds in rodents) observed
– Restoration of function without apparent damage to non-senescent cells
– The selectivity for senescent over healthy cells was confirmed across multiple organ systems

Potentially expected in humans (from community reports and mechanism):
– Injection site reactions: Burning, redness, swelling, stinging — reported as significant with SC large-volume injections (larger dose volumes than typical peptides)
– Flu-like symptoms: Mild fever, fatigue, malaise in the 24–72 hours following injection — possibly from immune clearance of apoptotic senescent cell debris
– Fatigue: Commonly reported in the 24–48 hours post-administration
– Inflammatory markers: Temporary elevation possible as dying senescent cells release SASP factors before being cleared

⚠️ The ‘senolytic storm’ risk:
Rapid clearance of large numbers of senescent cells releases accumulated SASP cytokines simultaneously
This inflammatory burst can be clinically significant depending on senescent cell burden
Gradual dosing protocols (starting with low doses) are recommended to assess individual response

⚠️ p53 reactivation concerns:
FOXO4-DRI releases p53 in senescent cells → apoptosis
In theory, p53 reactivation in non-senescent rapidly dividing cells (e.g., bone marrow, gut epithelium, cancer cells) could have off-target effects
Selectivity appears high in animal models but human translation is not confirmed

Contraindications

Based on mechanism, animal study design, and clinical reasoning:

Absolute avoid:
– Active malignancy: p53 release from FOXO4 sequestration could have unpredictable effects in tumor biology — some cancer cells use FOXO4 sequestration to survive; releasing p53 might be anti-tumor OR disruptive depending on cancer type. Oncologist consultation required.
– Pregnancy: No safety data; p53-mediated apoptosis in rapidly dividing fetal cells is theoretically dangerous
– Children and adolescents: Rapidly dividing cells in development; no safety data

Strong caution:
– Bone marrow suppression or cytopenias: p53 activity in hematopoietic progenitors could worsen
– Patients on chemotherapy or radiotherapy: Both cause senescence; the senescent cell burden may be very high — rapid clearance could cause severe SASP-related inflammation
– Concurrent use of multiple senolytics: Absolute caution — never combine; risk of inflammatory senolytic storm

D-amino acid consideration:
– Some individuals may react to D-amino acid peptides differently than L-amino acid peptides — immune recognition of unnatural D-configurations is not fully characterized in humans
– Hypersensitivity to FOXO4-DRI or synthesis byproducts: Unknown incidence; purity ≥98% minimizes this risk

Pharmacology

FOXO4-DRI is a D-retro-inverso (DRI) peptide — one of the most specialized peptide design strategies in contemporary research:

D-Retro-Inverso design:
– All amino acids are in the D-configuration (mirror images of natural L-amino acids)
– The amino acid sequence is reversed (C-terminus to N-terminus inverted)
– Despite these double modifications, the spatial arrangement of functional groups in 3D space is maintained — the peptide can still bind its target protein (p53)
– Result: Proteolytic enzymes cannot cleave D-amino acid bonds → exceptionally long in vivo stability vs. natural L-peptides

Target: FOXO4 protein — specifically the FOXO4 domain that binds p53 (analogous to a BH3-like motif)

Senescent cell biology context:
– In normal (non-senescent) cells: FOXO4 is not robustly expressed; p53 is free to trigger apoptosis when needed
– In senescent cells: FOXO4 is highly overexpressed → FOXO4 sequesters p53 in the nucleus → BLOCKS p53-dependent apoptosis → senescent cells become resistant to programmed death → they persist and secrete SASP

MW: ~3,975 Daltons (approximate)
Synthesis: Requires specialized solid-phase peptide synthesis (SPPS) with D-amino acid building blocks; technically challenging; higher cost than standard L-peptides
Purity requirement: ≥98% HPLC — critical to eliminate toxic synthesis impurities that co-elute with target peptide at lower purity thresholds

A 2025 Nature Communications study provided high-resolution structural insights into the FOXO4-p53 binding interface, validating the mechanistic basis of FOXO4-DRI’s design.

Mechanism of action

1. FOXO4-DRI Competes for p53 Binding (core mechanism):
FOXO4-DRI binds to the FOXO4 protein at the same domain that normally sequesters p53
→ FOXO4-DRI outcompetes FOXO4 for p53 binding
→ p53 is RELEASED from FOXO4 sequestration

2. p53 Nuclear Export and Apoptosis Induction (senescent cell-selective):
Released p53 →

translocates to mitochondria →
triggers mitochondrial permeability transition →
releases cytochrome c →
activates caspase cascade → APOPTOSIS

Then,

This pathway is specifically activated in SENESCENT cells because:
– Only senescent cells overexpress FOXO4 at levels sufficient to sequester p53
– Only senescent cells depend on FOXO4-p53 interaction for survival
– Healthy cells have low FOXO4 expression → FOXO4-DRI finds no target → no effect on healthy cells

3. Selectivity for Senescent Cells (key claimed advantage):
In the 2017 Cell study: FOXO4-DRI induced apoptosis in senescent human fibroblasts, IMR90 cells, and naturally aged mouse cells.
This selectivity appeared across multiple cell types in the mouse study

4. SASP Reduction (downstream benefit):
Elimination of senescent cells → reduces release of SASP factors (IL-6, IL-8, MMPs, etc.)
→ Reduced chronic inflammation in surrounding tissue
→ Improved tissue microenvironment for healthy cell function

5. Tissue Function Restoration (observed in aged mice):
Reduced senescent cell burden → improved function in tissues where senescent cells had accumulated
→ Kidney: improved glomerular filtration and tubular markers
→ Muscle: improved exercise tolerance and fitness
→ Skin: restored fur density in aged mice

Result Claims By Different Companies

Baar et al. / Erasmus University Medical Center (2017 Cell paper — landmark study):

– Aged fast-aging (XpdTTD/TTD) mice treated with FOXO4-DRI (5 mg/kg IP, 3x/week):
→ Restored fitness (exercise capacity, running speed on treadmill) vs. PBS-treated controls
→ Restored fur density (alopecia reversed)
→ Improved renal function (creatinine, urea metrics)
→ Reduced SA-β-galactosidase staining (biomarker of senescent cells) in kidney tissue
→ No observed toxicity to blood parameters, vital organs, or non-senescent cells

– Chemotherapy-induced senescence model (doxorubicin-treated mice):
→ FOXO4-DRI restored normal hematopoietic progenitor cell recovery
→ Cleared chemotherapy-induced senescent bone marrow cells faster than controls

– Leydig cell aging study (Zhang et al., 2020):
→ FOXO4-DRI improved testosterone production in aged mice by clearing senescent Leydig cells in testes

Disclaimer

This content about “FOXO4-DRI” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.